Financial Performance - Operating revenue for the first quarter of 2025 reached CNY 193,752,584.37, representing a year-on-year increase of 26.08%[11] - Net profit attributable to shareholders for the first quarter of 2025 was CNY 12,036,941.28, up 9.66% from the same period last year[11] - Total revenue for Q1 2025 reached ¥193,752,584.37, a significant increase from ¥153,676,683.10 in Q1 2024, representing a growth of approximately 26%[42] - Net profit for Q1 2025 reached CNY 12,036,709.84, an increase of 9.5% compared to CNY 10,995,156.82 in Q1 2024[43] - Basic and diluted earnings per share for Q1 2025 were both CNY 0.10, compared to CNY 0.09 in Q1 2024, indicating a 11.1% increase[44] - Total comprehensive income for Q1 2025 was CNY 12,036,709.84, compared to CNY 10,995,156.82 in Q1 2024, marking a growth of 9.5%[45] Cash Flow - The company's cash flow from operating activities showed a net outflow of CNY 117,262,155.18, a significant decline of 322.16% compared to the previous year[11] - Cash inflow from operating activities in Q1 2025 was CNY 168,207,462.98, slightly up from CNY 167,865,939.47 in Q1 2024[46] - The net cash flow from operating activities was -117,262,155.18 yuan, compared to -27,776,476.13 yuan in the previous year, indicating a significant decline in operational performance[47] - Total cash inflow from operating activities was 198,188,870.74 yuan, while cash outflow was 242,008,072.68 yuan, resulting in a net cash flow of -43,819,201.94 yuan for the current period[48][49] - The ending cash and cash equivalents balance was 307,223,402.68 yuan, down from 343,713,408.93 yuan year-over-year[47] Assets and Liabilities - Total assets as of March 31, 2025, were CNY 1,171,324,695.19, a decrease of 0.69% compared to the end of the previous year[11] - The company's total liabilities as of March 31, 2025, were RMB 314,708,949.37, compared to RMB 320,627,164.03 at the end of 2024[37] - The company's current assets totaled RMB 754,981,365.53, slightly down from RMB 760,988,526.04 at the end of 2024[35] - Total liabilities decreased to ¥219,484,431.03 as of March 31, 2025, down from ¥246,776,215.36 as of December 31, 2024, reflecting a decline of about 11%[41] Shareholder Information - The total number of ordinary shareholders was 5,716 as of the end of the reporting period[18] - The largest shareholder, Beijing Huikang Information Consulting Center, holds 28,461,255 shares, representing 22.86% of total shares[20] - The total shares held by the top ten shareholders amount to 74,890,742, which is 60.15% of the total shares[20] - The company has no pledged or judicially frozen shares among the top shareholders[21] Research and Development - Research and development expenses for Q1 2025 were ¥8,612,602.44, compared to ¥7,460,042.17 in Q1 2024, representing an increase of approximately 15%[42] - Research and development expenses for Q1 2025 amounted to CNY 6,775,364.99, an increase from CNY 5,974,323.69 in Q1 2024, reflecting a growth of 13.4%[44] Share Repurchase and Equity Plans - The company repurchased shares, resulting in treasury stock increasing by 191.90% to CNY 21,773,789.03[13] - The company approved a share repurchase plan with a budget of no less than RMB 10 million and no more than RMB 20 million, with a maximum repurchase price of RMB 13 per share[28] - As of December 31, 2024, the company repurchased 567,746 shares, accounting for 0.46% of the total share capital, with a total expenditure of RMB 5,680,553.06, which is 28.40% of the planned repurchase budget[28] - The maximum repurchase price was adjusted to RMB 25 per share, and the implementation period was extended to March 25, 2025[29] Commitments and Legal Matters - The company has not engaged in any litigation, arbitration, or external guarantees during the reporting period[23] - There are no significant related party transactions or fund misappropriation issues reported[23] - The company has disclosed commitments and has fulfilled them as per the prospectus[24] - The company has ongoing commitments that are being fulfilled as disclosed previously[31]

Product Innovation and Development - In 2024, Kangbiter launched new weight management products and upgraded its whey protein ultra product, winning the "Nutritional Food Technology Innovation Award" at the IWF Shanghai International Fitness Expo[8]. - Kangbiter's whey protein ultra product received widespread recognition, winning the 2024 Global Food Innovation Award bronze medal[9]. - The company is focusing on product innovation, launching the CPT pro specialized nutrition formula whey protein to enhance protein absorption efficiency[49]. - The company has completed the development of white kidney bean extract tablets, targeting consumers who enjoy carbohydrates but are concerned about weight management[95]. - The development of a CLA fish oil fat-reducing beverage has been completed, with successful sensory testing[95]. - The company has achieved batch production of slow-release creatine tablets, expanding its market presence among fitness enthusiasts[95]. - The company has successfully developed a range of ready-to-eat foods, including fried rice and chicken sticks, with plans for mass production and sales[96]. - The company has completed the industrialization of biscuit products, addressing issues related to microbial contamination and improving taste[96]. - The company is in the process of developing a new type of puffed protein bar, focusing on texture and stability improvements[96]. - The company has optimized the production process for energy gels, transitioning from contract manufacturing to in-house production, reducing costs[95]. - The company is developing a high-efficiency peptide drink aimed at post-exercise recovery, with a shelf life of over 12 months[104]. Financial Performance - The company's revenue for 2024 reached ¥1,040,013,192.71, representing a 23.34% increase compared to ¥843,220,191.54 in 2023[31]. - The net profit attributable to shareholders for 2024 was ¥89,313,991.99, a slight increase of 1.38% from ¥88,101,313.18 in 2023[31]. - The gross profit margin for 2024 decreased to 39.41% from 40.09% in 2023[31]. - Total assets at the end of 2024 amounted to ¥1,179,520,735.98, reflecting a 10.34% increase from ¥1,068,961,077.66 at the end of 2023[32]. - The company's total liabilities increased by 18.20% to ¥320,627,164.03 in 2024 from ¥271,250,624.62 in 2023[32]. - The return on equity (ROE) based on net profit attributable to shareholders was 10.76% in 2024, down from 11.50% in 2023[31]. - The company's cash flow from operating activities for 2024 was ¥132,159,732.23, a decrease of 10.83% from ¥148,208,544.00 in 2023[32]. - The accounts receivable turnover ratio improved to 14.84 in 2024 from 11.41 in 2023[33]. - The inventory turnover ratio increased to 3.02 in 2024, compared to 2.82 in 2023[33]. - The company's debt-to-asset ratio (consolidated) was 27.18% in 2024, up from 25.38% in 2023[32]. - The total profit for 2024 is ¥102,713,973.86, showing a minor difference of -0.10% from the earnings forecast[34]. Market Position and Recognition - The company was awarded the "Annual High Growth Award" on the Tmall health platform, leading the health track in the domestic health product industry[8]. - Kangbiter was listed in the "2024 Beijing Manufacturing Enterprises Top 100" and "2024 Beijing Specialized and Innovative Enterprises Top 100," reflecting its recognition in promoting high-quality economic development[10]. - The company established a digital sports health nutrition industry integration community with Beijing Sport University and Guangzhou City Vocational College[7]. - The company achieved a "Five-Star Credit Rating" in the corporate credit rating assessment, showcasing its strong corporate strength and credibility[9]. - The company is positioned in the rapidly growing sports nutrition food industry, with significant market potential due to low product penetration and increasing consumer awareness[53]. - The global sports nutrition market size grew from 16.314 billion USD in 2017 to 18.56 billion USD in 2022, and is projected to reach 25.191 billion USD by 2026[56]. Corporate Governance and Management - The company has established a robust governance structure, ensuring compliance with relevant laws and regulations[178]. - The board of directors consists of 7 members, while the supervisory board has 3 members and there are 6 senior management personnel[158]. - The company has implemented a performance evaluation mechanism for senior management, linking their compensation to performance indicators[198]. - The company maintains independence in operations, personnel, assets, institutions, and finances, ensuring no conflicts with shareholders[194]. - The supervisory board confirmed that the board of directors operated in compliance with resolutions from shareholder meetings, with no major risks identified[193]. Research and Development - The company maintains a robust R&D model, focusing on self-developed products and structured project management[42]. - The procurement system is designed to ensure quality through a multi-level evaluation mechanism for suppliers[43]. - The company applied for 38 patents in 2024, including 3 invention patents, and currently holds 198 authorized patents, comprising 103 invention patents, 60 utility model patents, and 35 design patents[52]. - The total number of R&D personnel decreased slightly to 100, with a proportion of 12.7% of total employees[92]. Strategic Partnerships and Collaborations - The company engaged in deep cooperation discussions with JD Health and Tmall Health to promote the healthy development of the sports nutrition industry[9]. - The company has established partnerships with universities to accelerate technological innovation in the sports nutrition sector[52]. Employee and Shareholder Information - The total number of employees increased from 795 to 901, representing a growth of approximately 13.3%[167]. - The company has a stock incentive plan with 710,000 shares that are currently unexercised[166]. - The company has repurchased 1,366,126 shares, accounting for 1.10% of the total share capital, and spent approximately 19.99 million yuan on this buyback[174]. - The largest shareholder, Beijing Huikang Information Consulting Center, holds 22.86% of the company’s shares, totaling 28,461,255 shares[138]. Risks and Challenges - The company acknowledges significant uncertainties in achieving its 2025 operational goals due to macroeconomic conditions and market demand fluctuations[109]. - The company faces risks related to actual control by major shareholders, which could impact strategic decisions and shareholder interests[110]. - The company recognizes competitive risks from both domestic and international brands in the expanding sports nutrition market[111].

Financial Performance - The company reported a basic earnings per share of 0.1000 yuan for Q1 2025, an increase of 11.11% compared to 0.0900 yuan in Q1 2024 [1] - The total revenue for Q1 2025 was 1.94 billion yuan, reflecting a growth of 25.97% from 1.54 billion yuan in Q1 2024 [1] - The net profit for Q1 2025 was 0.12 billion yuan, which is a 9.09% increase from 0.11 billion yuan in Q1 2024 [1] - The return on equity (ROE) for Q1 2025 was 1.39%, slightly up from 1.37% in Q1 2024 [1] Shareholder Structure - The top ten unrestricted shareholders collectively hold 64.55 million shares, accounting for 56.97% of the circulating shares, with a change of 162,700 shares from the previous period [1] - Beijing Huilikang Information Consulting Center (Limited Partnership) remains the largest shareholder with 28.46 million shares, representing 25.12% of the total share capital [2] - Notable changes include a decrease of 101.20 million shares held by Yin Hui International Limited and a decrease of 124.00 million shares held by Chen Qingyue [2] Dividend Policy - The company has announced that it will not distribute dividends or transfer shares this time [3]

一、募集资金基本情况 证券代码：833429 证券简称：康比特 公告编号：2025-026 北京康比特体育科技股份有限公司 关于使用部分闲置募集资金进行现金管理的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 2022 年 12 月 2 日，北京康比特体育科技股份有限公司（以下简称"公司"） 发行普通股 20,490,000 股，发行方式为向不特定合格投资者公开发行，发行价 格为 8 元/股，募集资金总额为 163,920,000.00 元，实际募集资金净额为 138,389,404.38 元，到账时间为 2022 年 12 月 7 日。 二、募集资金使用情况 （一）募集资金使用情况和存储情况 截至 2024 年 12 月 31 日，公司上述发行股份的募集资金使用情况具体如下： 单位：元 | | | | | | 投入进 | | | | --- | --- | --- | --- | --- | --- | --- | --- | | | 募集资金用 | | 募集资金计划 | 累计投入募集 | 度（ ...

证券代码：833429 证券简称：康比特 公告编号：2025-027 北京康比特体育科技股份有限公司 关于公司向银行申请综合授信的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 为优化工作流程，公司董事会授权董事长签署相关协议，并由公司财务部门 在银行综合授信额度范围内办理相关手续。 为满足公司日常经营业务发展及需要，北京康比特体育科技股份有限公司 （以下简称"公司"）2025 年拟向中国工商银行股份有限公司北京昌平支行申 请综合授信，授信额度不超过 5,000 万元人民币，期限一年；向中国民生银行股 份有限公司北京分行申请综合授信，授信额度不超过 10,000 万元人民币，期限 不超过三年；向北京银行股份有限公司中关村分行申请综合授信，授信可申请多 笔，总授信额度不超过 10,000 万元人民币，期限不超过四年；向招商银行股份 有限公司北京分行申请综合授信，授信额度不超过 4,000 万元人民币，期限一年； 向中信银行股份有限公司北京分行申请综合授信，授信额度不超过 2,000 万元人 民币授信 ...

证券代码：833429 证券简称：康比特 公告编号：2025-031 北京康比特体育科技股份有限公司 董事会对会计师事务所履职情况评估报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载，误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 北京康比特体育科技股份有限公司（以下简称"公司"）聘请容诚会计师事 务所（特殊普通合伙）（以下简称"容诚"）作为公司 2024 年年度审计机构。 根据财政部及证监会颁布的《国有企业、上市公司选聘会计师事务所管理办法》 等法律法规的要求，公司对容诚在近一年审计中的履职情况进行了评估，具体情 况如下： 一、会计师事务所基本情况 1. 基本信息 会计师事务所名称：容诚会计师事务所（特殊普通合伙） 注册地址：北京市西城区阜成门外大街 22 号 1 幢 10 层 1001-1 至 1001-26 首席合伙人：刘维 2024 年度末合伙人数量：212 人 2024 年度末注册会计师人数：1,552 人 成立日期：2013 年 12 月 10 日 组织形式：特殊普通合伙 2024 年度末签署过证券服务业务审计报告的注册会计师人数：7 ...

太平洋证券股份有限公司 关于北京康比特体育科技股份有限公司 公司存续至 2024 年度的募集资金为 2022 年公开发行募集资金。 （一）实际募集资金金额和资金到账时间 2022 年 11 月 15 日，中国证券监督管理委员会出具《关于同意北京康比特 体育科技股份有限公司向不特定合格投资者公开发行股票注册的批复》（证监许 可〔2022〕2880 号），同意公司向不特定合格投资者公开发行股票的注册申请。 2022 年 12 月 8 日，北京证券交易所出具《关于同意北京康比特体育科技股份有 限公司股票在北京证券交易所上市的函》（北证函〔2022〕259 号），经批准， 公司股票于 2022 年 12 月 15 日在北京证券交易所上市。公司本次发行股数为 20,490,000 股（超额配售选择权行使前），发行价格为人民币 8.00 元/股，募集资 金总额为人民币 163,920,000.00 元，扣除发行费用人民币 25,530,595.62 元（不含 增值税），募集资金净额为人民币 138,389,404.38 元，募集资金已于 2022 年 12 月 7 日划至公司指定账户。上述募集资金到位情况已经容诚会计师事 ...

证券代码：833429 证券简称：康比特 公告编号：2025-021 北京康比特体育科技股份有限公司 2024 年度内部控制自我评价报告 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要 求（以下简称"企业内部控制规范体系"），结合北京康比特体育科技股份有限 公司（以下简称"公司"）内部控制制度，在内部控制日常监督和专项监督的基 础上，董事会对公司 2024 年 12 月 31 日（内部控制评价报告基准日）的内部控 制有效性进行了评价。 （一）内部控制评价范围 公司按照风险导向原则确定纳入评价范围的主要单位、业务和事项。纳入评 价范围的单位包括：合并报表范围内的公司及下属子公司。纳入评价范围的事项 包括：内部控制环境、风险评估过程、主要控制活动、信息系统与沟通、对控制 的监督；纳入评价范围的主要业务包括：重大投资、对外担保、关联交易、信息 披露、销售与收款、采购与付款、生产管理、人力资源、货币资金等内容。 上述纳入评价范围的业务和事项涵盖了公司经营管理的主要方面，不存在重 大遗漏。 一、重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其 有效性，并如实披露内部控制评 ...

证券代码：833429 证券简称：康比特 公告编号：2025-024 北京康比特体育科技股份有限公司 关于2025年度董事、监事及高级管理人员薪酬方案的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载，误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 北京康比特体育科技股份有限公司（以下简称"公司"）根据《公司法》 《公司章程》及相关法律、法规和规范性文件的规定，结合经营发展等实际情 况，参考行业、地区薪酬水平，制定了2025年度董事、监事及高级管理人员薪 酬方案。现将具体情况公告如下： 一、适用对象 在公司领取薪酬的董事、监事和高级管理人员。 二、适用期限 2025年1月1日至2025年12月31日。 三、审议程序 （一）公司董事薪酬方案 1、2025年4月15日，公司董事会薪酬与考核委员会召开2025年度第一次会议， 审议《关于2025年度董事、高级管理人员薪酬方案的议案》，全体委员回避表决， 将该议案直接提交公司董事会审议。 3、2025年4月16日，公司召开第六届监事会第十次会议，审议《关于2025年 度监事薪酬方案的议案》，全体监事回避表 ...

证券代码：833429 证券简称：康比特 公告编号：2025-025 北京康比特体育科技股份有限公司 关于使用闲置自有资金购买理财产品的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、 委托理财概述 （一） 委托理财目的 为了提高公司自有闲置资金使用效率，合理利用资金获取较好的投资回 报，在不影响公司主营业务正常发展的前提下，公司拟使用自有闲置资金购买 理财产品，为公司与股东创造更大的收益。理财产品主要是安全性高、流动性 好、可以保障投资本金安全的理财产品。 （二） 委托理财金额和资金来源 在不影响公司主营业务正常发展的前提下，公司拟使用额度不超过 50,000 万元的自有闲置资金购买理财产品。 （三） 委托理财方式 二、 决策与审议程序 2025 年 4 月 16 日，公司第六届董事会第十一次会议审议通过了《关于使 用闲置自有资金购买理财产品的议案》，表决结果：同意票数 7 票，反对票数 0 票，弃权票数 0 票。 本议案尚需提交股东大会审议。 三、 风险分析及风控措施 1、 预计委托理财额 ...